<p>In this phase Ib/II clinical trial, the investigators evaluated the efficacy and safety of the combination of palbociclib with bazedoxifene in patients with a metastatic endocrine-resistant hormone receptor-positive, HER2-negative breast cancer. Furthermore, whole exome sequencing of cell-free tumor DNA was done on serial samples from these patients, revealing potential molecular changes associated with mechanisms of resistance. </p>

Phase IB/II Study of Bazedoxifene in Combination with Palbociclib in    Patients with Endocrine Resistant Hormone Receptor-Positive Breast    Cancer

Breast Neoplasms study with WGS, WXS data on dbGaP (32 participants)

phs002802 — Phase IB/II Study of Bazedoxifene in Combination with Palbociclib in    Patients with Endocrine Resistant Hormone Receptor-Positive Breast    Cancer

Phase IB/II Study of Bazedoxifene in Combination with Palbociclib in Patients with Endocrine Resistant Hormone Receptor-Positive Breast Cancer

Description

Applying For Access

Summary